scholarly journals Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-β-secreting cells and suppressing chemokine expression

2000 ◽  
Vol 12 (10) ◽  
pp. 1449-1457 ◽  
Author(s):  
Jia-Bin Sun ◽  
Bao-Guo Xiao ◽  
Marianne Lindblad ◽  
Bin-Ling Li ◽  
Hans Link ◽  
...  
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor ◽  
Basic Protein ◽  
Transforming Growth Factor Β ◽  
Cholera Toxin B Subunit ◽  
Autoimmune Encephalomyelitis ◽  
Toxin B ◽  
Cholera Toxin B ◽  
B Subunit ◽  
Experimental Autoimmune

scholarly journals Immune Response Induced by Recombinant Mycobacterium bovis BCG Producing the Cholera Toxin B Subunit

2003 ◽  
Vol 71 (5) ◽  
pp. 2933-2937 ◽  
Author(s):  
Franck Biet ◽  
Laurent Kremer ◽  
Isabelle Wolowczuk ◽  
Myriam Delacre ◽  
Camille Locht
Keyword(s):  
Cholera Toxin ◽  
Mycobacterium Bovis ◽  
Transforming Growth Factor ◽  
Vaccine Development ◽  
Mucosal Vaccine ◽  
Cholera Toxin B Subunit ◽  
Toxin B ◽  
Cholera Toxin B ◽  
B Subunit ◽  
Iga Response

ABSTRACT The pentameric form of the cholera toxin B subunit (CTB) is known to be a strong mucosal adjuvant and stimulates antigen-specific secretory immunoglobulin A (IgA) and systemic antibody responses to antigens when given by mucosal routes. To deliver CTB for prolonged periods of time to the respiratory mucosa, we constructed a Mycobacterium bovis bacillus Calmette-Guérin (BCG) strain that produces and secretes assembled pentameric CTB. Mice immunized intranasally (i.n.) with recombinant BCG (rBCG) developed a stronger anti-BCG IgA response in bronchoalveolar lavage fluids (BALF) than mice immunized with nonrecombinant BCG. The total IgA response in the BALF of mice immunized with rBCG was also stronger than that in BALF of mice immunized with the nonrecombinant strain. The induction of IgA was well correlated with an increased production of transforming growth factor β1. Simultaneous administration of intraperitoneally delivered ovalbumin and of i.n. delivered CTB-producing BCG induced a long-lasting ovalbumin-specific mucosal IgA response as well as a systemic IgG response, both of which were significantly higher than those in mice immunized with nonrecombinant BCG together with ovalbumin. These results suggest that the CTB-producing BCG may be a powerful adjuvant to be considered for future mucosal vaccine development.

scholarly journals Spray-Dried Formulation of Epicertin, a Recombinant Cholera Toxin B Subunit Variant That Induces Mucosal Healing

Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 576
Author(s):  
Micaela A. Reeves ◽  
Joshua M. Royal ◽  
David A. Morris ◽  
Jessica M. Jurkiewicz ◽  
Nobuyuki Matoba ◽  
...  
Keyword(s):  
Gastric Acid ◽  
Cholera Toxin ◽  
Oral Formulation ◽  
Size Exclusion ◽  
Cholera Toxin B Subunit ◽  
Toxin B ◽  
Cholera Toxin B ◽  
B Subunit ◽  
Enteric Coated ◽  
Spray Dried

Epicertin (EPT) is a recombinant variant of the cholera toxin B subunit, modified with a C-terminal KDEL endoplasmic reticulum retention motif. EPT has therapeutic potential for ulcerative colitis treatment. Previously, orally administered EPT demonstrated colon epithelial repair activity in dextran sodium sulfate (DSS)-induced acute and chronic colitis in mice. However, the oral dosing requires cumbersome pretreatment with sodium bicarbonate to conserve the acid-labile drug substance while transit through the stomach, hampering its facile application in chronic disease treatment. Here, we developed a solid oral formulation of EPT that circumvents degradation in gastric acid. EPT was spray-dried and packed into enteric-coated capsules to allow for pH-dependent release in the colon. A GM1-capture KDEL-detection ELISA and size-exclusion HPLC indicated that EPT powder maintains activity and structural stability for up to 9 months. Capsule disintegration tests showed that EPT remained encapsulated at pH 1 but was released over 180 min at pH 6.8, the approximate pH of the proximal colon. An acute DSS colitis study confirmed the therapeutic efficacy of encapsulated EPT in C57BL/6 mice upon oral administration without gastric acid neutralization pretreatment compared to vehicle-treated mice (p < 0.05). These results provide a foundation for an enteric-coated oral formulation of spray-dried EPT.

Sign in / Sign up

Export Citation Format

Share Document